• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharma (NQ: ARWR )

    21.39 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arrowhead Pharma

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Arrowhead Pharmaceuticals's Return On Capital Employed Overview
    Via Benzinga
    Analyst Ratings for Arrowhead Pharmaceuticals
    Via Benzinga
    Earnings Preview For Arrowhead Pharmaceuticals
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
    Via Benzinga
    Why Arrowhead Pharmaceuticals Stock Is Diving Today
    Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with 
    Via Benzinga
    CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
    Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
    Via Investor's Business Daily
    Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
    From Arrowhead Pharmaceuticals Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
    The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
    Via Investor's Business Daily
    Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Earnings Scheduled For November 28, 2022
    Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion. 
    Via Benzinga
    Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
    From Royalty Pharma plc
    Via GlobeNewswire
    Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
    Upgrades 
    Via Benzinga
    Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
    From Arrowhead Pharmaceuticals Inc.
    Via Business Wire
    Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals
      Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter: 
    Via Benzinga
    Arrowhead Pharmaceuticals: Q3 Earnings Insights
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.